A PHASE 1/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALS
Latest Information Update: 11 Jun 2024
At a glance
- Drugs BNT 161 (Primary) ; Tozinameran (Primary) ; Influenza virus vaccine
- Indications COVID 2019 infections; Influenza virus infections
- Focus Adverse reactions
- Sponsors BioNTech
Most Recent Events
- 19 Feb 2024 Status changed from active, no longer recruiting to completed.
- 11 Dec 2023 Planned End Date changed from 13 Dec 2024 to 29 Dec 2023.
- 11 Dec 2023 Planned primary completion date changed from 13 Dec 2024 to 29 Dec 2023.